On a quest not just to catch up with, but leapfrog, Amgen and Mirati in the KRAS race, Roche has released early monotherapy data on its in-house candidate across a variety of cancers.
Roche, which presented some divarasib data at the AACR conference in April, spelled out the most comprehensive…
Click here to view original post
